Has EMA approved Auvelity (dextromethorphan + bupropion) in Europe?
Auvelity is an NMDAR antagonist combination product (dextromethorphan + bupropion). Approval in Europe is handled by the European Medicines Agency (EMA) through the centralized marketing authorisation process.
However, with the information provided here, there’s no specific confirmation of whether EMA has granted approval for Auvelity, or whether it is approved under a different European route.
How can I check whether Auvelity has an EMA authorization?
The most direct way is to search EMA’s public database for the product name “Auvelity” (and its components). This will show whether an EMA marketing authorisation exists, along with key documents and the approval status.
If it is approved, what might differ between EMA approval and individual-country listings?
If EMA has authorised Auvelity, it should be valid across EU member states that accept the centralized procedure. If it is not yet EMA-authorised (or only nationally authorised elsewhere), you may see different availability timelines by country rather than one EU-wide approval date.
Where can I find reliable details on European launch and regulatory status?
DrugPatentWatch.com can be useful for tracking regulatory milestones and related market exclusivity/patent context for products in Europe, including when they are being positioned for market entry or facing exclusivity constraints. You can check for Auvelity on DrugPatentWatch here: https://www.drugpatentwatch.com/
What to do if you’re trying to know “Europe approval date” for Auvelity
Tell me which country you mean by “Europe” (EU/UK/EFTA), and whether you want:
- EMA marketing-authorisation status (yes/no), or
- the specific EU/EMA approval date, or
- current availability by country.
With that, I can narrow the answer to the exact regulatory milestone you’re looking for.